Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: Artificial intelligence (AI) is reshaping molecular precision medicine through biomarker discovery, genomic variant interpretation, molecular imaging, multi-omics analysis, and patient-specific therapeutic support. In Saudi Arabia, genomic medicine and digital health initiatives are expanding, yet limited evidence explains how AI readiness supports molecular diagnostics, genomic testing, biobanking, biological sample traceability, and targeted therapy delivery. Methods: A structured cross-sectional survey was completed by 350 professionals from hospitals, molecular diagnostic laboratories, genomic testing centers, biomedical laboratories, biobanks, pharmaceutical and biologic suppliers, and healthcare service providers in Saudi Arabia. Data were analyzed using partial least squares structural equation modeling. Results: AI readiness strengthened molecular data interoperability, biological sample traceability, diagnostic responsiveness, biomarker-guided decision support, and precision medicine service performance. Respondents from more AI-ready organizations reported stronger diagnostic responsiveness and fewer perceived workflow delays. Discussion: The findings connect AI readiness with molecular diagnostics, genomic services, biomarker analytics, biobanking, and healthcare supply chain coordination, providing evidence to support AI-enabled molecular medicine transformation in Saudi Arabia.
Source: Frontiers in Digital Health
Authors: Islam El-Nakib, Karim Soliman
Institutions: Effat University, University of Business and Technology
Language: English
Subfield: Health Informatics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,077
OpenAlex ID: W7202345822